A Phase 1 interventional study of Single-ascending Dose (SAD) study and Food Effect (FE) study and Multiple-ascending Doses (MAD) study in Obesity With Cardiovascular Risk Study, sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.
Among the 188 studies in Obesity with a site in Australia, this one is the 99th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 33 in phase 1, reaches primary completion later than 29 of the 73 other live ones, and was the 188th registered.
11,556 studies on the registry are indexed under Obesity; 2,050 are open to participants now.
Browse Obesity studies →56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
Amgen · Sites in Australia, United States, Canada and 2 more countries
Ages 18–99
Verdiva Bio Dev Limited · Sites in Australia
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 34 · Phase 3 59 · Phase 4 8
First in 1995; this study’s year is marked. 41 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 103 is above the median of 67 across 9,027 interventional studies indexed under Obesity.
Median enrollment 180 across the 169 interventional studies, 626 across the 19 observational. Of the 97 that completed or were terminated, 14 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 188 have an industry lead sponsor. The 10 most frequent:
Chengdu Zenitar Biomedical Technology Co., Ltd is the lead sponsor of 24 studies on the registry; 13 are open to participants now.
Chengdu Zenitar Biomedical Technology Co., Ltd has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
25 of the studies in Obesity with a site in Australia that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 25 to your calendar (.ics) → With an account.
Among the 188 studies in Obesity with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study comprised of 3 parts, gradually investigating the safety, tolerance, PK and PD characteristics of the ZL-65 tablets in healthy adult participants and obesity with cardiovascular risk participants in Australia. The study results will provide important basis for formulating the subsequent study strategies and dosing plans.Part 1: Single-ascending Dose (SAD) study and Food Effect (FE) study;Part 2: Multiple-ascending Doses (MAD) study;Part 3: Obesity with cardiovascular risk study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- i, Healthy adult participants, regardless of gender, aged between 18 and 65 years old when the is signed; ii,Male participants with a body weight of >= 50.0 kg, female participants with a body weight of >= 45.0 kg; iii, Those who can understand the informed consent form, voluntarily participate in the trial and sign the informed consent form.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Single-ascending Dose (SAD) study and Food Effect (FE) study
Drug: Multiple-ascending Doses (MAD) study
Drug: Obesity with cardiovascular risk study
The SAD portion of the study consists of 5 cohorts. Dosing in these cohorts will precede sequentially: 5 mg, 10 mg, 25 mg, 40 mg and 50 mg cohorts.
The MAD portion of the study consists of 3 cohorts. Dosing in these cohorts will precede sequentially:10 mg, 25 mg and 40 mg cohorts.
This study intends to set up 2 dose cohorts, temporarily as follows: 1) 10 mg QD cohort, 2) 25 mg QD cohort.
Incidence of adverse events
including hematology, blood biochemistry, urinalysis, and coagulation function
Time frame: Day 1 to Day 21
ZL65 Pharmacokinetics (PK):Cmax
Time frame: 0-144 hours
ZL65 Pharmacokinetics (PK):Tmax
Time frame: 0-144 hours
ZL65 Pharmacokinetics (PK):AUC0-t
Time frame: 0-144 hours
ZL65 Pharmacokinetics (PK):t1/2
Time frame: 0-144 hours
Start is estimated for Nov 2026; primary completion for Sep 2027, 10 months later.
Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 10 months is above that.
Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chengdu Zenitar Biomedical Technology Co., Ltd →